Unknown

Dataset Information

0

Technologies for controlled, local delivery of siRNA.


ABSTRACT: The discovery of RNAi in the late 1990s unlocked a new realm of therapeutic possibilities by enabling potent and specific silencing of theoretically any desired genetic target. Better elucidation of the mechanism of action, the impact of chemical modifications that stabilize and reduce nonspecific effects of siRNA molecules, and the key design considerations for effective delivery systems has spurred progress toward developing clinically-successful siRNA therapies. A logical aim for initial siRNA translation is local therapies, as delivering siRNA directly to its site of action helps to ensure that a sufficient dose reaches the target tissue, lessens the potential for off-target side effects, and circumvents the substantial systemic delivery barriers. While locally injected or topically applied siRNA has progressed into numerous clinical trials, an enormous opportunity exists to develop sustained-release, local delivery systems that enable both spatial and temporal control of gene silencing. This review focuses on material platforms that establish both localized and controlled gene silencing, with emphasis on the systems that show most promise for clinical translation.

SUBMITTER: Sarett SM 

PROVIDER: S-EPMC4665980 | biostudies-other | 2015 Nov

REPOSITORIES: biostudies-other

altmetric image

Publications

Technologies for controlled, local delivery of siRNA.

Sarett Samantha M SM   Nelson Christopher E CE   Duvall Craig L CL  

Journal of controlled release : official journal of the Controlled Release Society 20151101


The discovery of RNAi in the late 1990s unlocked a new realm of therapeutic possibilities by enabling potent and specific silencing of theoretically any desired genetic target. Better elucidation of the mechanism of action, the impact of chemical modifications that stabilize and reduce nonspecific effects of siRNA molecules, and the key design considerations for effective delivery systems has spurred progress toward developing clinically-successful siRNA therapies. A logical aim for initial siRN  ...[more]

Similar Datasets

| S-EPMC3232066 | biostudies-literature
| S-EPMC9141514 | biostudies-literature
| S-EPMC5152672 | biostudies-literature
| S-EPMC4150469 | biostudies-literature
| S-EPMC5599180 | biostudies-literature
| S-EPMC5518795 | biostudies-literature
| S-EPMC2955163 | biostudies-literature
| S-EPMC6343727 | biostudies-literature
| S-EPMC6410566 | biostudies-literature
| S-EPMC7567411 | biostudies-literature